Related Experiment Video

Updated: Jul 23, 2026

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein
10:43

Expression, Detergent Solubilization, and Purification of a Membrane Transporter, the MexB Multidrug Resistance Protein

Published on: December 3, 2010

[Multidrug resistance mediated by membrane P-glycoprotein in acute myeloid leukemia]

Li-Ping Su1

  • 1Department of Hematology, The Second Teaching Hospital, Shanxi Medical University, Taiyuan 030001, China. lpsu588@sohu.com

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|October 25, 2003
PubMed

Insights

Drug resistance in acute leukemia is a major challenge. This review examines how intracellular drug transport, particularly the role of transporters like P-glycoprotein (P-gp), contributes to treatment failure in acute myeloid leukemia (AML).

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Chemotherapeutic drug resistance is a significant obstacle in treating acute leukemia.
  • Mechanisms include impaired apoptosis and reduced intracellular drug efficacy.
  • This review specifically addresses intracellular drug transport resistance.

Purpose of the Study:

  • To review the mechanisms of intracellular drug transport resistance in acute leukemia.
  • To discuss the role of specific ATP-binding cassette (ABC) transporters in multidrug resistance.
  • To explore the correlation between transporter expression and patient outcomes in acute myeloid leukemia (AML).

Main Methods:

  • Literature review focusing on intracellular drug transport mechanisms.
  • Analysis of studies investigating ATP-binding cassette (ABC) transporters, including P-glycoprotein (P-gp), multidrug resistance protein (MRP), and lung resistance protein (LRP).
  • Examination of correlations between transporter expression and clinical outcomes in acute myeloid leukemia (AML).

Main Results:

  • Expression of P-glycoprotein (P-gp) is generally linked to poorer prognosis in AML.
  • Expression of multidrug resistance-associated protein (MRP) and lung resistance protein (LRP) also shows a correlation with AML outcomes, though this is more debated.
  • Intracellular drug transport mechanisms are critical factors in chemotherapy resistance.

Conclusions:

  • Intracellular drug transport, mediated by transporters like P-gp, MRP, and LRP, plays a crucial role in acute leukemia treatment failure.
  • Understanding these mechanisms is vital for developing strategies to overcome drug resistance in AML.
  • Targeting these transporters may offer new therapeutic avenues for improving patient outcomes.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...